In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca, Novartis Continued Divestment Sprees In 2018, While Peers Joined The Action

Executive Summary

While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.

 

Advertisement

Related Content

Farewell To MedImmune: AstraZeneca Will Combine Large And Small Molecule Research
GSK Makes I-O Move With Merck KGaA Deal Worth Up To €3.7bn
AZ Management Shake-Up Sees CMO Bohen Exit
Pfizer Consumer Combo Deal Frees Capital For GSK Pharma Investment
Why The M&A Boom Many Expected In 2018 Didn’t Happen
Bold Brandicourt Plots Mega Sanofi And Boehringer Animal, Consumer Asset Swap

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV124216

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel